Prevalence and Predictors of Neoadjuvant Therapy for Stage IIIA Non-Small Cell Lung Cancer in the National Cancer Database: Importance of Socioeconomic Status and Treating Institution

被引:18
|
作者
Sher, David J. [1 ]
Liptay, Michael J. [2 ]
Fidler, Mary Jo [3 ]
机构
[1] Rush Univ, Med Ctr, Dept Radiat Oncol, Chicago, IL 60612 USA
[2] Rush Univ, Med Ctr, Dept Cardiothorac Surg, Chicago, IL 60612 USA
[3] Rush Univ, Med Ctr, Sect Med Oncol, Chicago, IL 60612 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2014年 / 89卷 / 02期
关键词
RANDOMIZED-TRIAL; PHASE-II; PREOPERATIVE CHEMOTHERAPY; RACIAL-DIFFERENCES; RADIATION-THERAPY; ONCOLOGY-GROUP; RADIOTHERAPY; SURGERY; CHEMORADIATION; CARCINOMA;
D O I
10.1016/j.ijrobp.2014.01.033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The optimal locoregional therapy for stage IIIA non-small cell lung cancer (NSCLC) is controversial, with definitive chemoradiation therapy (CRT) and neoadjuvant therapy followed by surgery (NT-S) serving as competing strategies. In this study, we used the National Cancer Database to determine the prevalence and predictors of NT in a large, modern cohort of patients. Methods and Materials: Patients with stage IIIA NSCLC treated with CRT or NT-S between 2003 and 2010 at programs accredited by the Commission on Cancer were included. Predictors were categorized as clinical, time/geographic, socioeconomic, and institutional. In accord with the National Cancer Database, institutions were classified as academic/research program and as comprehensive and noncomprehensive community cancer centers. Logistic regression and random effects multilevel logistic regression were performed for univariable and multivariable analyses, respectively. Results: The cohort consisted of 18,581 patients, 3,087 (16.6%) of whom underwent NT-S (10.6% induction CRT, 6% induction chemotherapy). The prevalence of NT-S was constant over time, but there were significant relative 31% and 30% decreases in pneumonectomy and right-sided pneumonectomy, respectively, over time (P trend <.02). In addition to younger age, lower T stage, and favorable comorbidity score, indicators of higher socioeconomic status were strong independent predictors of NT-S, including white race, higher income, and private/managed insurance. The type of institution (academic/research program vs comprehensive or noncomprehensive community cancer centers, odds ratio 1.54 and 2.08, respectively) strongly predicted NT-S, but treatment volume did not. Conclusions: Neoadjuvant therapy followed by surgery was an uncommon treatment approach in Commission on Cancer programs, and the prevalence of postinduction pneumonectomy decreased over time. Higher socioeconomic status and treatment at academic institutions were significant predictors of NT-S. Further research should be performed to enable a better understanding of these disparities. (C) 2014 Elsevier Inc.
引用
收藏
页码:303 / 312
页数:10
相关论文
共 50 条
  • [31] PREDICTORS OF TRIMODALITY THERAPY USE AND OVERALL SURVIVAL IN PATIENTS WITH STAGE III NON-SMALL CELL LUNG CANCER (NSCLC) IN THE NATIONAL CANCER DATABASE
    Fidler, Mary Jo
    Liptay, Micheal
    Bonomi, Philip
    Sher, David
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S137 - S138
  • [32] A Call for Careful Interpretation of Outcome of Nonsurgical Approach in Clinical Stage IIIa Non-Small Cell Lung Cancer in the National Cancer Database
    Cihoric, Nikola
    Filipovic, Nenad
    Jeremic, Branislav
    ANNALS OF THORACIC SURGERY, 2015, 99 (03) : 1111 - 1112
  • [33] Randomized controlled trial of neoadjuvant chemotherapy with cisplatin and vinorelbine in patients with stage IIIA non-small cell lung cancer in China
    Li, Jian
    Yu, Li-Chao
    Chen, Ping
    Shi, Sheng-Bing
    Dai, Chun-Hua
    Wu, Jian-Rong
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2009, 5 (02) : 87 - 94
  • [34] Surgical Management of Stage IIIA Non-small Cell Lung Cancer
    Omar Toubat
    Anthony W. Kim
    Current Pulmonology Reports, 2020, 9 : 151 - 163
  • [35] Stage III Non-small Cell Lung Cancer
    Rusch, Valerie W.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 37 (05) : 727 - 735
  • [36] Operation and adjuvant therapy of non-small cell lung cancer (Stage I to operable IIIA)
    Eberhardt, Wilfried
    Fietkau, Rainer
    Griesinger, Frank
    Passlick, Bernward
    Stuschke, Martin
    ONKOLOGIE, 2006, 29 : 7 - 10
  • [37] Neoadjuvant chemotherapy in non-small cell lung cancer: current state and future
    Mellas, N.
    Elmesbahi, O.
    Masbah, O.
    Errihani, H.
    BULLETIN DU CANCER, 2010, 97 (02) : 211 - 223
  • [39] Neoadjuvant strategy for stage IIIA-N2 non-small cell lung cancer: chemoradiation or chemotherapy alone?
    Situ, Dongrong
    Lin, Yongbin
    JOURNAL OF THORACIC DISEASE, 2017, 9 (09) : 2746 - 2748
  • [40] Neoadjuvant Versus Adjuvant Systemic Therapy for Early-Stage Non-Small Cell Lung Cancer: The Changing Landscape Due to Immunotherapy
    John, Ajoy Oommen
    Ramnath, Nithya
    ONCOLOGIST, 2023, 28 (09) : 752 - 764